Viz.ai, a pioneering force in AI-driven disease detection and intelligent care coordination, has attained a significant milestone with the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking algorithm, Viz ICH Plus. This innovative software streamlines the process of identifying, labeling, and quantifying intracerebral hemorrhages (ICH) on non-contrast computed tomography (NCCT) images, empowering clinicians with precise data for expedited and informed treatment strategies.

Enhancing Clinical Decision-Making

"The ability and mobility to obtain accurate and quantifiable measurements of intracerebral hemorrhages through Viz ICH Plus significantly enhances our decision-making process," remarked Dr. Peter Kan, MD, MPH, FRCSC, FAANS, Professor and Chair of the Department of Neurosurgery at the University of Texas Medical Branch. "This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."

Addressing Critical Needs in Stroke Care

Intracerebral hemorrhage, constituting up to 15% of all strokes, necessitates urgent intervention due to its high morbidity and mortality rates. Timely and accurate volume measurements of brain bleeds are imperative for assessing severity, monitoring progression, and devising effective treatment plans. Viz ICH Plus enables seamless integration into existing workflows for radiologists, neurologists, and neurosurgeons, automating the manual process of measuring brain bleeds and facilitating swift clinical decisions.

A Leap Forward in Patient Care

"At Viz.ai, our mission is rooted in advancing healthcare through innovation. Viz ICH Plus exemplifies our dedication to enhancing patient care by leveraging technology," affirmed Jayme Strauss, Chief Clinical Officer at Viz.ai. "We are excited to introduce a product that bridges the gap between AI capabilities and improved patient outcomes."

Empowering Clinicians with Cutting-Edge Technology

The Viz ICH Plus software is available on the AI-powered Viz.ai One™ solution, an enterprise platform that has been clinically validated and deployed across more than 1,500 hospitals in the United States. By harnessing the power of AI, Viz.ai continues to revolutionize stroke care, providing clinicians with the tools they need to deliver timely, accurate, and life-saving interventions for patients with intracerebral hemorrhage.